BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed INCY catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:b6472b9a42c9cec6b342@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:INCY P2 readout (est.): A Study to Evaluate the Efficacy and Safety
  Study of Povorcitinib in Participants With Inadequately Controlled Modera
 te to Severe Asthma
DESCRIPTION:A Study to Evaluate the Efficacy and Safety Study of Povorcitin
 ib in Participants With Inadequately Controlled Moderate to Severe Asthma\
 nNCT05851443 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Incyte Corporatio
 n\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nTicker INCY (confidence 0.9)\nSource: https://clinicaltrials.gov/st
 udy/NCT05851443\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05851443
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:90437b35da8f89cd6b48@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261226
DTEND;VALUE=DATE:20261227
SUMMARY:INCY P3 readout (est.): STOP-HS LTE
DESCRIPTION:A Study to Evaluate the Long-Term Safety and Efficacy of Povorc
 itinib in Participants With Moderate to Severe Hidradenitis Suppurativa\nN
 CT06212999 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Incyte Corporation\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nTicker INCY (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT06212999\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06212999
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ff46a0283d6da3f3f508@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:INCY P1/P2 readout (est.): A Ph1b/2 Study of Axatilimab Monotherapy
  in Chinese Participants With Recurrent or Refractory cGVHD
DESCRIPTION:A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participant
 s With Recurrent or Refractory cGVHD\nNCT06843408 | PHASE1/PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: Incyte Corporation\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nTicker INCY (confidence
  0.9)\nSource: https://clinicaltrials.gov/study/NCT06843408\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06843408
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4296b2cc94d89523ab99@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260518
DTEND;VALUE=DATE:20260519
SUMMARY:INCY APPROVAL: ZYNYZ
DESCRIPTION:Approved 2026-05-18: ZYNYZ (BLA761334 SUPPL9)\nConfidence: conf
 irmed\nTicker INCY (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761334\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761334
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:f186341b1711c72ca8e1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260501
DTEND;VALUE=DATE:20260502
SUMMARY:INCY APPROVAL: JAKAFI XR
DESCRIPTION:Approved 2026-05-01: JAKAFI XR (NDA217180 ORIG1)\nConfidence: c
 onfirmed\nTicker INCY (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217180\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217180
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:19eb112e16c765914b7c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260330
DTEND;VALUE=DATE:20260331
SUMMARY:INCY APPROVAL: ZYNYZ
DESCRIPTION:Approved 2026-03-30: ZYNYZ (BLA761334 SUPPL8)\nConfidence: conf
 irmed\nTicker INCY (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761334\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761334
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a0b9354742361643ace2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251217
DTEND;VALUE=DATE:20251218
SUMMARY:INCY APPROVAL: ZYNYZ
DESCRIPTION:Approved 2025-12-17: ZYNYZ (BLA761334 SUPPL5)\nConfidence: conf
 irmed\nTicker INCY (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761334\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761334
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
